The health-related, social, and economic ... - Cure Parkinson's

Cure Parkinson's

26,582 members27,897 posts

The health-related, social, and economic consequences of parkinsonism: a controlled national study

CPT_Helen profile image
CPT_HelenPartner
1 Reply

Parkinson's disease (PD) and atypical parkinsonism (AP) cause a significant socioeconomic burden, but there is insufficient information about the total disease burden at a national level. Thus, the goal of this study was to estimate the excess direct and indirect costs of PD and AP in a national sample.

Using records from the Danish National Patient Registry (1997-2007), 13,400 PD and 647 AP patients were identified and compared with, respectively, 53,600 and 2,588 control cases randomly selected with respect to age, gender, civil status, and geographic location. Direct costs including frequencies of primary and sector contacts and procedures, and medication from primary and secondary sectors were obtained from the Danish Ministry of Health, the Danish Medicines Agency, and the National Health Security. Indirect costs, which included labor supply and social transfer payments, were based on income data derived from the Coherent Social Statistics.

Patients with PD and AP had significantly higher rates of health-related contact and medication use and a higher socioeconomic cost. Furthermore, they had very low employment rates, and those in employment had a lower income level than employed control subjects. The annual mean excess health-related cost was <euro>6,500 ($8,975/£5,543) and <euro>9,771 ($13,491/£8,332) for each patient with PD and AP, respectively. In addition, the patients with PD and AP received an annual mean excess social transfer income of <euro>324 (£276/$447) and <euro>844 (£719/$1,165), respectively.

The employment- and health-related consequences could be identified up to 8 years before the first diagnosis and increased with disease advancement. PD and AP have major socioeconomic consequences for patients and society. The health effects are present for up to more than 8 years before a diagnosis of PD/AP.

August 2011

Jennum P, Zoetmulder M, Korbo L, Kjellberg J

--------------------------------------------------------------------------------

¦Journal of Neurology 2011 Aug. Vol 258 (8); 1497-1506

¦doi: 10.1007/s00415-011-5969-1

Written by
CPT_Helen profile image
CPT_Helen
Partner
To view profiles and participate in discussions please or .
Read more about...
1 Reply
CPT_Tom profile image
CPT_Tom

There is an interesting article by Richard Dodel "Interpreting Health Economics Data in Parkinson's Disease" at the following address - definitely worth a look. touchneurology.com/files/ar...

Not what you're looking for?

You may also like...

A Drug Shown To Actually Slow Progression in Humans

The team identified 2880 Parkinson's patients taking one of the three drugs that target PGK1 and a...
jimcaster profile image

Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study.

Antibiotic exposure and risk of Parkinson's disease in finland: A nationwide case-control study....

Ever wonder about questions that are in the minds of key Parkinson's researchers? Here's a sample . . . .

Here are some of the most important unanswered questions in Parkinson’s disease research from some...
FMundo profile image

The FMT / PD Study Results I Had Been Waiting For Were Released Today And It Was Very Disappointing

The Helsinki FMT/PD study results were done last August, but the release was delayed to meet...
chartist profile image

Another antihistamine proves promising

It appears that if one has PD or prodromal PD and suffers from allergies, fexofenadine (Allegra)...
Rufous2 profile image